Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1224P - Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions

Date

16 Sep 2021

Session

ePoster Display

Presenters

Petros Christopoulos

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

P. Christopoulos1, S.I. Ou2, J. Lin3, D. Berg4, J. Hong5, Y. Yin6, J. Lin7, V. Bunn3, H.M. Lin8, M. Mehta9, M. Thomas10

Author affiliations

  • 1 Department Of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), 69126 - Heidelberg/DE
  • 2 Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange/US
  • 3 Statistics, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 4 Oncology Research And Development, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 5 Epidemiology, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 6 Observational Research Analytics, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 7 Oncology Statistics, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 8 Global Evidence And Outcome, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 9 Clinical Science, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 10 Department Of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg/DE
More

Abstract 1224P

Background

EGFR exon 20 insertion (ex20ins) mutations are rare, and data on clinical outcomes with immunotherapy (IO) in these patients are scarce. Per National Comprehensive Cancer Network guidelines, IO monotherapy is not recommended over targeted therapies for non–small cell lung cancer (NSCLC) patients with an oncogenic driver. To determine the efficacy of IO monotherapy in the second-line setting and beyond (≥2nd-line) for EGFRex20ins+ NSCLC, we conducted a systematic review and meta-analysis of real-world objective response rate (ORR) data.

Methods

We analyzed ORRs of ≥2nd-line IO monotherapies in EGFRex20ins+ NSCLC from: (1) PubMed literature search for clinical studies reporting ORR, disease control rate (DCR), or progression-free survival (PFS); (2) longitudinal data from the United States Flatiron Health Research Database; (3) a retrospective chart review from 12 German oncology centers; and (4) prior anticancer therapy and associated response data from a single-arm, phase I/II study of mobocertinib, an oral EGFR tyrosine kinase inhibitor targeting EGFRex20ins, in EGFRex20ins+ NSCLC patients previously treated with ≥2nd-line IO.

Results

From the meta-analysis of all data, the calculated ORR [95% confidence intervals] for ≥2nd-line IO monotherapy in patients with EGFRex20ins+ NSCLC was 3.5% [0.6%, 9.9%] (Table). Across sources (N=91), reported ORRs ranged from 0% to 14.3% (1/7 patients in single study), with 2 total responses; DCRs ranged from 23.8% to 30.0%, and median PFS ranged from 2.3 months to 4.0 months. Reported data were limited by small number of patients and studies reporting mixed lines of therapy (≥2nd-line). Table: 1224P

Data source Reported ORR, n/N (%)
Takeda M. (Oncotarget. 2018) 1/7 (14.3%)
LC-SCRUM-JAPAN/Udagawa (J Thorac Oncol. 2019) 0/21 (0%)
Yang G. (Lung Cancer. 2020) 0/2 (0%)
Flatiron database 1/20 (5%)
German chart review 0/10 (0%)
Mobocertinib study 0/31 (0%)
Meta-analysis Mean ORR [2.5%, 97.5%]
3.5% [0.6%, 9.9%]

Conclusions

Results of this meta-analysis suggest that IO monotherapies are not effective in the ≥2nd-line setting for patients with EGFRex20ins+ NSCLC, which further highlights the need for novel treatment options in this population.

Clinical trial identification

Editorial acknowledgement

Professional medical writing assistance was provided by Amy Zannikos, PharmD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Millennium Pharmaceuticals, Inc.

Legal entity responsible for the study

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Funding

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure

P. Christopoulos: Financial Interests, Personal, Other, Research funding: AstraZeneca, Novartis, Roche, Takeda; Financial Interests, Personal, Other, advisory board/lecture fees: AstraZeneca, Boehringer Ingelheim, Chugai, Novartis, Pfizer, Roche, Takeda. S.I. Ou: Financial Interests, Personal, Other, Personal fees: Pfizer, AstraZeneca, Takeda/ARIAD, Roche/Genentech, Daiichi Sankyo, Janssen/Johnson & Johnson; Financial Interests, Personal, Stocks/Shares: Turning Point Therapeutics, Elevation Oncology. J. Lin: Financial Interests, Personal, Full or part-time Employment: Takeda. D. Berg: Financial Interests, Personal, Full or part-time Employment: Takeda. J. Hong: Financial Interests, Personal, Full or part-time Employment: Takeda. Y. Yin: Financial Interests, Personal, Full or part-time Employment: Takeda. J. Lin: Financial Interests, Personal, Full or part-time Employment: Takeda. V. Bunn: Financial Interests, Personal, Full or part-time Employment: Takeda. H.M. Lin: Financial Interests, Personal, Full or part-time Employment: Takeda. M. Mehta: Financial Interests, Personal, Full or part-time Employment: Takeda. M. Thomas: Financial Interests, Personal, Other, Honoraria: AbbVie, BMS, MSD, AstraZeneca, Novartis, Roche, Takeda, Lilly, Chugai, Celgene, Boehringer Ingelheim, Pfizer, Janssen; Financial Interests, Personal, Other, travel: AbbVie, BMS, MSD, AstraZeneca, Novartis, Roche, Takeda, Lilly, Chugai, Celgene, Boehringer Ingelheim, Pfizer; Financial Interests, Personal, Advisory Role: AbbVie, BMS, MSD, AstraZeneca, Novartis, Roche, Takeda, Lilly, Chugai, Celgene, Boehringer Ingelheim, Pfizer, Janssen; Financial Interests, Institutional, Other, Research funding: BMS, AstraZeneca, Roche, Takeda.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings